Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Additional file 1 of Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation

Autor: Korshunov, Andrey, Okonechnikov, Konstantin, Schmitt-Hoffner, Felix, Ryzhova, Marina, Sahm, Felix, Stichel, Damian, Schrimpf, Daniel, Reuss, David E., Sievers, Philipp, Suwala, Abigail Kora, Kumirova, Ella, Zheludkova, Olga, Golanov, Andrey, Jones, David T. W., Pfister, Stefan M., Kool, Marcel, Deimling, Andreas Von

Additional file 1.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a28989bb3ee0f1b7003560618da743

Targeting brain tumor stem cells by interfering with choline metabolism: Evidence for an EMT-choline oncometabolic network

Autor: Koch, Katharina, Hartmann, Roland, Suwala, Abigail Kora, Maciaczyk, Donata, Willbold, Dieter, Kahlert, Ulf Dietrich, Maciaczyk, Jaroslaw

Publikováno v: 68. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 7. Joint Meeting mit der Society of British Neurological Surgeons (SBNS); 20170514-20170517; Magdeburg; DOCMi.03.05 /20170609/

Objective: Glioblastoma (GBM) is the most lethal primary brain tumor in adults with a median survival of less than two years. High levels of therapy resistance, strong cellular invasiveness and rapid cell growth demand aggressive multimodal therapies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8669c45d7d078c8e04ba0599503a19e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Inhibition of Wnt/beta-catenin signaling downregulates expression of aldehyde dehydrogenase isoform 3A1 (ALDH3A1) to reduce resistance against temozolomide in glioblastoma in vitro .

Autor: Suwala AK; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany., Koch K; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany., Rios DH; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany., Aretz P; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany., Uhlmann C; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany., Ogorek I; Department of Neuropathology, University Hospital Düsseldorf, Düsseldorf, Germany., Felsberg J; Department of Neuropathology, University Hospital Düsseldorf, Düsseldorf, Germany., Reifenberger G; Department of Neuropathology, University Hospital Düsseldorf, Düsseldorf, Germany.; German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, German Cancer Research Center (DKFZ), Heidelberg, Germany., Köhrer K; Genomics and Transcriptomics Laboratory, Biological and Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Germany., Deenen R; Genomics and Transcriptomics Laboratory, Biological and Medical Research Center (BMFZ), Heinrich Heine University, Düsseldorf, Germany., Steiger HJ; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany., Kahlert UD; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany.; German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, German Cancer Research Center (DKFZ), Heidelberg, Germany., Maciaczyk J; Department of Neurosurgery, University Hospital Düsseldorf, Düsseldorf, Germany.; Department of Surgical Sciences-Neurosurgery, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

Publikováno v: Oncotarget [Oncotarget] 2018 Apr 27; Vol. 9 (32), pp. 22703-22716. Date of Electronic Publication: 2018 Apr 27 (Print Publication: 2018).